CORAT Therapeutics GmbH obtained regulatory authorization for clinical phase Ib/II trial with the SARS-CoV-2 neutralizing human antibody COR-101 ...Middle East

BRAUNSCHWEIG, Germany, March 16, 2021 /PRNewswire/ -- CORAT Therapeutics GmbH obtained the regulatory approval as well as the favorable opinion from the central ethics committee to conduct the clinical phase Ib/II trial with its antibody COR-101 against COVID-19. COR-101 is a neutralizing...

Hence then, the article about corat therapeutics gmbh obtained regulatory authorization for clinical phase ib ii trial with the sars cov 2 neutralizing human antibody cor 101 was published today ( Tuesday 16/03/2021 - 10:23 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( CORAT Therapeutics GmbH obtained regulatory authorization for clinical phase Ib/II trial with the SARS-CoV-2 neutralizing human antibody COR-101 )

Also on site :

• AI Wars: Why Microsoft, Google and Amazon Are All Fighting Over Power
• Hisense RGB MiniLED podporuje operácie videoasistenta rozhodcov počas Majstrovstiev sveta vo futbale FIFA World Cup 2026™ v Medzinárodnom vysielacom centre
• /C O R R E C T I O N -- Quigley-Simpson/